Amgen NASDAQ: AMGN p. farmaceutyczny, biotechnologiczny

[slayer74]

Investing.com - Amgen (NASDAQ: AMGN) reported second quarter EPS of $5.00, $0.51 better than the analyst estimate of $4.49. Revenue for the quarter came in at $7B versus the consensus estimate of $6.67B.

Guidance
Amgen sees FY 2023 EPS of $17.80-$18.80 versus the analyst consensus of $17.75.

Amgen sees FY 2023 revenue of $26.60B-$27.40B versus the analyst consensus of $26.56B.

Amgen's stock price closed at $230.70. It is down -2.46% in the last 3 months and down -6.59% in the last 12 months.

Amgen saw 7 positive EPS revisions and 12 negative EPS revisions in the last 90 days. See Amgen's stock price’s past reactions to earnings here.

[slayer74]

(Reuters) - Amgen (NASDAQ:AMGN) said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics (NASDAQ:HZNP) after it received the go-ahead from the U.S. Federal Trade Commission (FTC) last month on certain conditions.

Under the settlement terms with the FTC following its lawsuit to block the deal, Amgen is prevented from using anticompetitive tactics to extend the market dominance of Horizon's thyroid eye disease treatment Tepezza and gout drug Krystexxa.

The FTC's antitrust lawsuit had raised concerns over increased oversight on mergers and acquisitions in a sector that often turns to consolidation to power future growth as patents on older treatments expire.

The deal closure was within the fourth-quarter timeline set by the two companies.